Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: IPBizPatent reform and IBM's questionable patents
By Lawrence B. Ebert, Esq.
On the one hand, there is Jon Dudas talking about IBM's toilet queue patent. Nate Anderson wrote:
[the patent] in many ways is symptomatic of the problems facing his office [the USPTO]. At a talk today [March 27] at the Tech Policy Summit in Hollywood, Dudas shed some light on why companies file such patents in the first place, and what his office hopes to do about it.
IBM, who Dudas only referred to as a "Fortune 10 company," is routinely at or near the top of the heap when it comes to number of US patents obtained in a given year. While companies generally want patents in order to protect intellectual property, that's not the only a reason for seeking patents. Dudas noted that Wall Street loves it when companies file patents, since patent numbers can be used as an easy proxy for innovation and R&D work. The sheer number of patents can also make it easier to strike cross-licensing agreements with other companies, as it makes a given patent portfolio look broader and stronger.
These things don't "promote innovation," as Dudas noted, but they do make increasing economic sense for many businesses. The result has been predictable; a surge in bad applications.
On the other hand, we have Bessen and Meurer and Princeton University Press talking about the "urban legend" of IBM's licensing. In a tiff with Joff Wild, one had the following.
In responding to Joff Wild of IAM, the authors [BM] wrote:
As we discuss in the book, p. 117, our estimates correspond well with IBM's actual performance. In fact, the "over $1 billion a year from licensing its patents" is an "urban legend" promoted by patent boosters; the actual figure is between $100 and $200 million and that is gross of the costs of IBM's several hundred lawyers.
Wild in turn noted:
The $1 billion of licensing revenue as an urban legend ?promoted by patent boosters? claim is an extremely serious one. In effect, what Jim and Michael are saying here is that there are a lot of people who have been economical with the truth about IBM?s licensing activities from the early 1990s onwards.
IPBiz notes one has both Director Dudas and Bessen/Meurer suggesting IBM's patents are not so valuable.
***See also
http://ipbiz.blogspot.com/2008/03/dudas-ibms-toilet-queue-patent-and.html
http://ipbiz.blogspot.com/2008/03/pinocchios-for-intellectual-property.html [One notes that Hillary Clinton changed the
story, but Lemley never did.]
http://ipbiz.blogspot.com/2008/03/more-on-bessen-and-meurer.html
Full post as published by IPBiz on March 27, 2008 (boomark / email).
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Texas, USA
alleging the Medical Malpractice and Tort Reform Act of 2003 violates several provisions of the Constitution.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
Lenders Fined
Ryland Group Inc. settles $370,000 questionable lending suit.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Repossessed car wins $700,000 Settlement
A class action lawsuit that was brought against Virginia Beach-based Tidewater Finance Co., alleging that the company had questionable repossession practices, has been settled.










